Bucharest

• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu … Ended recruitment
  2024-510965-41-00 5 2024-09-03 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
• A study to investigate the safety and efficacy of fostemsavir in heavily treatment experienced people living with HIV-1 resistant to other d … Ended recruitment
  2024-513930-39-00 5 2024-08-30 Heavily Treatment Experienced Subjects Infected with Multi-drug Resist
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper … Ended recruitment
  2023-508670-28-00 5 2024-08-26 Hypertension
• A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours Ended recruitment
  2023-508764-30-00 1 2024-07-31 Locally advanced or metastatic solid tumors
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arte … Ended recruitment
  2023-506334-75-00 5 2024-07-12 Pulmonary Arterial Hypertension
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves … Ended recruitment
  2023-507685-10-00 5 2024-05-30 High-Risk Non-muscle-invasive Bladder Cancer
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• Effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a sin … Ended recruitment
  2023-503719-13-00 5 2024-05-06 Prevention of clinically relevant bleeding events in patients treated
• Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solutio … Ended recruitment
  2023-506917-23-00 4 2024-04-19 patients with mild to moderate left-sided ulcerative colitis
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended recruitment
  2023-503288-40-00 5 2024-01-26 Unresectable or Metastatic Melanoma
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or … Ended recruitment
  2023-503452-27-00 5 2024-01-02 Adult patients with follicular B-cell non-Hodgkin lymphoma grade 1-3A,
• A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients Ended recruitment
  2023-505160-12-00 5 2023-12-04 Essential Thrombocythaemia

Showing 361–384 of 653 trials